• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by PAVmed Inc.

    4/8/26 8:40:32 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care
    Get the next $PAVM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    PAVmed Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    70387R502

    (CUSIP Number)
    03/27/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    70387R502


    1Names of Reporting Persons

    NAGELBERG DAVID S
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    546,964.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    546,964.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    546,964.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    70387R502


    1Names of Reporting Persons

    David S. Nagelberg 2003 Revocable Trust Dtd. 07/02/03
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FLORIDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    461,539.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    461,539.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    461,539.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Trust


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PAVmed Inc.
    (b)Address of issuer's principal executive offices:

    360 MADISON AVENUE, 25TH FLOOR, NEW YORK, NEW YORK, 10017.
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is filed by the David S. Nagelberg 2003 Revocable Trust Dtd. 07/02/03 ("Trust") and David Nagelberg ("Mr. Nagelberg," and together with the Trust, the "Reporting Persons"). Mr. Nagelberg controls the Trust. The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 99.1 to the Schedule 13G, pursuant to which such Reporting Persons have agreed to file the Schedule 13G and all amendments thereto jointly in accordance with the provisions of Rule 13d-1(k) of the Act. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this Schedule 13G should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock reported herein.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is c/o Graubard Miller, 405 Lexington Avenue, 44th Floor, New York, New York 10174.
    (c)Citizenship:

    The Trust is a trust governed by the laws of Florida. Mr. Nagelberg is a citizen of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP Number(s):

    70387R502
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The Trust beneficially owns 461,539 shares of Common Stock. Mr. Nagelberg may be deemed to beneficially own the shares of Common Stock held by the Trust, because Mr. Nagelberg controls the Trust. Mr. Nagelberg beneficially owns an additional 85,425 shares of Common Stock.
    (b)Percent of class:

    The Trust beneficially owns 7.2% of the outstanding shares of Common Stock. Mr. Nagelberg beneficially owns 8.6% of the outstanding shares of Common Stock. The percentage of beneficial ownership is calculated based on 6,383,089 shares of Common Stock outstanding as of March 27, 2026, as set forth in the Company's annual report on Form 10-K filed on March 27, 2026.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Trust: 461,539 shares Mr. Nagelberg: 546,964 shares

     (ii) Shared power to vote or to direct the vote:

    Trust: 0 shares Mr. Nagelberg: 0 shares

     (iii) Sole power to dispose or to direct the disposition of:

    Trust: 461,539 shares Mr. Nagelberg: 546,964 shares

     (iv) Shared power to dispose or to direct the disposition of:

    Trust: 0 shares Mr. Nagelberg: 0 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    NAGELBERG DAVID S
     
    Signature:/s/ David Nagelberg
    Name/Title:David Nagelberg
    Date:04/08/2026
     
    David S. Nagelberg 2003 Revocable Trust Dtd. 07/02/03
     
    Signature:/s/ David Nagelberg
    Name/Title:David Nagelberg, Trustee
    Date:04/08/2026
    Exhibit Information

    99.1 Joint Filing Agreement (filed herewith).

    Get the next $PAVM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

    NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT. The fireside chat will be webcast live and available via the Investor Relations Section of the Lucid Diagnostics website or by clicking here.  A

    4/9/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

    Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's cur

    4/2/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submissionLucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM ESTNEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagno

    3/30/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by PAVmed Inc.

    SCHEDULE 13G - PAVmed Inc. (0001624326) (Subject)

    4/8/26 8:40:32 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PAVmed Inc. (0001624326) (Filer)

    3/30/26 8:10:19 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - PAVmed Inc. (0001624326) (Filer)

    3/27/26 5:15:28 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Tasso Partners, Llc

    3 - PAVmed Inc. (0001624326) (Issuer)

    4/6/26 9:46:16 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Aklog Lishan

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 6:53:45 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Mcgrath Dennis M

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 4:51:51 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on PAVmed with a new price target

    Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00

    3/30/21 6:22:24 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lake Street Capital reiterated coverage on PAVmed with a new price target

    Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously

    2/22/21 4:33:18 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Leadership Updates

    Live Leadership Updates

    View All

    PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

    Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's cur

    4/2/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Financials

    Live finance-specific insights

    View All

    PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submissionLucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM ESTNEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagno

    3/30/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Processed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full

    3/26/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    11/14/24 10:02:46 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    9/23/24 8:46:15 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    2/14/24 3:38:38 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care